SG11201503821YA - Oligonucleotide conjugates - Google Patents
Oligonucleotide conjugatesInfo
- Publication number
- SG11201503821YA SG11201503821YA SG11201503821YA SG11201503821YA SG11201503821YA SG 11201503821Y A SG11201503821Y A SG 11201503821YA SG 11201503821Y A SG11201503821Y A SG 11201503821YA SG 11201503821Y A SG11201503821Y A SG 11201503821YA SG 11201503821Y A SG11201503821Y A SG 11201503821YA
- Authority
- SG
- Singapore
- Prior art keywords
- oligonucleotide conjugates
- conjugates
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12192773 | 2012-11-15 | ||
EP13153296 | 2013-01-30 | ||
EP13157237 | 2013-02-28 | ||
EP13174092 | 2013-06-27 | ||
PCT/EP2013/073858 WO2014076195A1 (en) | 2012-11-15 | 2013-11-14 | Oligonucleotide conjugates |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201503821YA true SG11201503821YA (en) | 2015-06-29 |
Family
ID=49584733
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804331TA SG10201804331TA (en) | 2012-11-15 | 2013-11-14 | Oligonucleotide conjugates |
SG11201503821YA SG11201503821YA (en) | 2012-11-15 | 2013-11-14 | Oligonucleotide conjugates |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201804331TA SG10201804331TA (en) | 2012-11-15 | 2013-11-14 | Oligonucleotide conjugates |
Country Status (22)
Country | Link |
---|---|
US (4) | US20150291958A1 (ja) |
EP (3) | EP2920307B1 (ja) |
JP (3) | JP6452614B2 (ja) |
KR (2) | KR20150083920A (ja) |
CN (3) | CN104837996A (ja) |
AU (2) | AU2013346767B2 (ja) |
BR (2) | BR112015011112A2 (ja) |
CA (2) | CA2889044A1 (ja) |
DK (2) | DK2920307T3 (ja) |
ES (1) | ES2724853T3 (ja) |
HK (2) | HK1210213A1 (ja) |
HR (1) | HRP20190826T1 (ja) |
IL (2) | IL238448B (ja) |
MX (2) | MX363068B (ja) |
MY (1) | MY173826A (ja) |
NZ (1) | NZ708171A (ja) |
PL (1) | PL2920304T3 (ja) |
RU (3) | RU2653438C2 (ja) |
SG (2) | SG10201804331TA (ja) |
SI (1) | SI2920304T1 (ja) |
WO (2) | WO2014076195A1 (ja) |
ZA (1) | ZA201503375B (ja) |
Families Citing this family (259)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK3222722T3 (da) | 2002-11-18 | 2019-06-17 | Roche Innovation Ct Copenhagen As | Antisense-design |
CA2966011C (en) | 2008-10-15 | 2021-10-19 | Ionis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
WO2010064146A2 (en) | 2008-12-02 | 2010-06-10 | Chiralgen, Ltd. | Method for the synthesis of phosphorus atom modified nucleic acids |
KR101885383B1 (ko) | 2009-07-06 | 2018-08-03 | 웨이브 라이프 사이언시스 리미티드 | 신규한 핵산 프로드러그 및 그의 사용 방법 |
EP2620428B1 (en) | 2010-09-24 | 2019-05-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
DK2756080T3 (da) | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | Multimeriske oligonukleotidforbindelser |
US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
AU2013262709A1 (en) | 2012-05-16 | 2015-01-22 | Rana Therapeutics, Inc. | Compositions and methods for modulating MECP2 expression |
US10174315B2 (en) | 2012-05-16 | 2019-01-08 | The General Hospital Corporation | Compositions and methods for modulating hemoglobin gene family expression |
BR112014028634A2 (pt) | 2012-05-16 | 2017-06-27 | Rana Therapeutics Inc | composições e métodos para modulação da expressão de utrn |
EP2850186B1 (en) | 2012-05-16 | 2018-12-19 | Translate Bio MA, Inc. | Compositions and methods for modulating smn gene family expression |
WO2013173598A1 (en) | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating atp2a2 expression |
DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
JP6453212B2 (ja) | 2012-07-13 | 2019-01-16 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | キラル制御 |
US20150247141A1 (en) | 2012-09-14 | 2015-09-03 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
AU2013346767B2 (en) | 2012-11-15 | 2019-04-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
RU2018108405A (ru) * | 2013-01-30 | 2019-02-26 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты углевода и lna-олигонуклеотида |
JP6649248B2 (ja) | 2013-05-01 | 2020-02-19 | レグルス セラピューティクス インコーポレイテッド | 細胞取り込みの向上のための化合物および方法 |
EA034731B1 (ru) | 2013-05-01 | 2020-03-13 | Регьюлэс Терапьютикс Инк. | Соединения на основе микрорнк и способы модулирования активности mir-122 |
NZ631552A (en) | 2013-05-01 | 2017-02-24 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv expression |
US9943604B2 (en) | 2013-09-20 | 2018-04-17 | Ionis Pharmaceuticals, Inc. | Targeted therapeutic nucleosides and their use |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
US9994846B2 (en) | 2013-10-25 | 2018-06-12 | Regulus Therapeutics Inc. | MicroRNA compounds and methods for modulating miR-21 activity |
EP3095459A4 (en) | 2014-01-15 | 2017-08-23 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having antitumor effect and antitumor agent |
WO2015108047A1 (ja) | 2014-01-15 | 2015-07-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
SG10201912897UA (en) | 2014-01-16 | 2020-02-27 | Wave Life Sciences Ltd | Chiral design |
KR102287532B1 (ko) * | 2014-01-30 | 2021-08-11 | 에프. 호프만-라 로슈 아게 | 생분해성 컨쥬게이트를 갖는 폴리 올리고머 화합물 |
WO2015143245A1 (en) | 2014-03-19 | 2015-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating ataxin 2 expression |
HUE055877T2 (hu) | 2014-03-19 | 2021-12-28 | Ionis Pharmaceuticals Inc | Ataxin-2 expresszióját módosító készítmények |
HRP20220798T1 (hr) | 2014-04-01 | 2022-10-14 | Biogen Ma Inc. | Pripravci za modulaciju ekspresije sod-1 |
CA2946003A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating angiopoietin-like 3 expression |
EP3757215A3 (en) | 2014-05-01 | 2021-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
CN106232804B (zh) | 2014-05-01 | 2019-10-25 | Ionis制药公司 | 用于调节补体因子b表达的组合物和方法 |
AU2015252917B2 (en) | 2014-05-01 | 2019-09-26 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating PKK expression |
GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
CN106559995A (zh) | 2014-08-07 | 2017-04-05 | 莱古路斯治疗法股份有限公司 | 靶向代谢紊乱的微小rna |
US10436802B2 (en) | 2014-09-12 | 2019-10-08 | Biogen Ma Inc. | Methods for treating spinal muscular atrophy |
US20170327524A1 (en) | 2014-10-10 | 2017-11-16 | Hoffmann-La Roche, Inc. | Galnac phosphoramidites, nucleic acid conjugates thereof and their use |
BR112017009504A2 (pt) * | 2014-11-10 | 2018-02-06 | Glaxosmithkline Ip No 2 Ltd | métodos para tratar e para curar uma infecção por hcv, e, composição farmacêutica. |
WO2016096938A1 (en) | 2014-12-16 | 2016-06-23 | Roche Innovation Center Copenhagen A/S | Chiral toxicity screening method |
AU2015364508A1 (en) * | 2014-12-18 | 2017-07-06 | Alnylam Pharmaceuticals, Inc. | ReversirTM compounds |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
EP3256591A4 (en) | 2015-02-13 | 2018-08-08 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
DK3277814T3 (da) | 2015-04-03 | 2020-08-24 | Univ Massachusetts | Oligonukleotidforbindelser til målretning mod huntingtin-mrna |
RS62672B1 (sr) | 2015-04-03 | 2021-12-31 | Univ Massachusetts | Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja |
WO2016167780A1 (en) | 2015-04-16 | 2016-10-20 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
EP3334499A4 (en) * | 2015-08-14 | 2019-04-17 | University of Massachusetts | BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES |
DK3341479T3 (da) * | 2015-08-24 | 2020-02-24 | Roche Innovation Ct Copenhagen As | LNA-G-Proces |
WO2017053995A1 (en) * | 2015-09-25 | 2017-03-30 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
KR20180073584A (ko) | 2015-10-02 | 2018-07-02 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 올리고뉴클레오타이드 접합 방법 |
KR20180056766A (ko) | 2015-10-09 | 2018-05-29 | 웨이브 라이프 사이언시스 리미티드 | 뉴클레오티드 조성물 및 이의 방법 |
WO2017068087A1 (en) | 2015-10-22 | 2017-04-27 | Roche Innovation Center Copenhagen A/S | Oligonucleotide detection method |
EP3371201A4 (en) * | 2015-11-06 | 2019-09-18 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
BR122023026882A2 (pt) | 2015-11-06 | 2024-01-23 | Ionis Pharmaceuticals, Inc | Uso de um composto oligomérico |
RS61529B9 (sr) | 2015-11-12 | 2024-04-30 | Hoffmann La Roche | Oligonukleotidi za indukovanje ekspresije paternalnog ube3a |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
US10907160B2 (en) | 2016-01-05 | 2021-02-02 | Ionis Pharmaceuticals, Inc. | Methods for reducing LRRK2 expression |
JP6853193B2 (ja) * | 2016-01-29 | 2021-03-31 | 協和キリン株式会社 | 核酸複合体 |
CA3011894A1 (en) | 2016-01-31 | 2017-08-03 | University Of Massachusetts | Branched oligonucleotides |
TWI783434B (zh) | 2016-03-07 | 2022-11-11 | 美商愛羅海德製藥公司 | 治療性化合物之標靶性配體 |
JP6748219B2 (ja) | 2016-03-14 | 2020-08-26 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pd−l1発現低減用のオリゴヌクレオチド |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
AU2017234678A1 (en) | 2016-03-16 | 2018-08-16 | Ionis Pharmaceuticals, Inc. | Methods of modulating KEAP1 |
MA45328A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
EP3228326A1 (en) * | 2016-04-05 | 2017-10-11 | Silence Therapeutics GmbH | Nucleic acid linked to a trivalent glycoconjugate |
KR102369898B1 (ko) * | 2016-04-08 | 2022-03-03 | 트랜슬레이트 바이오 인코포레이티드 | 다량체 코딩 핵산 및 그 용도 |
US11248019B2 (en) | 2016-04-14 | 2022-02-15 | Hoffmann-La Roche Inc. | Trityl-mono-GalNAc compounds and their use |
KR20190003740A (ko) * | 2016-05-06 | 2019-01-09 | 아이오니스 파마수티컬즈, 인코포레이티드 | Glp-1 수용체 리간드 모이어티 컨쥬게이트된 올리고뉴클레오티드 및 이의 용도 |
MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
WO2017219017A1 (en) | 2016-06-17 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
MX2018015722A (es) | 2016-07-01 | 2019-05-27 | Hoffmann La Roche | Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1). |
WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
JOP20170056B1 (ar) | 2016-09-02 | 2021-08-17 | Arrowhead Pharmaceuticals Inc | مركبات ترابطية مستهدفة |
CN109661233A (zh) | 2016-10-06 | 2019-04-19 | Ionis 制药公司 | 缀合低聚化合物的方法 |
JOP20190104A1 (ar) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن atxn3 |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
US20190367920A1 (en) | 2017-01-13 | 2019-12-05 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb1 expression |
US20190345495A1 (en) | 2017-01-13 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating nfkb2 expression |
EP3568477A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rela expression |
EP3568478A1 (en) | 2017-01-13 | 2019-11-20 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating rel expression |
WO2018130585A1 (en) | 2017-01-13 | 2018-07-19 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides for modulating relb expression |
WO2018165541A1 (en) * | 2017-03-10 | 2018-09-13 | The Board Of Regents Of The University Of Texas System | Treatment of fuchs' endothelial corneal dystrophy |
WO2018164275A1 (ja) | 2017-03-10 | 2018-09-13 | 国立研究開発法人国立成育医療研究センター | アンチセンスオリゴヌクレオチドおよび糖原病Ia型予防または治療用組成物 |
WO2018215049A1 (en) | 2017-05-23 | 2018-11-29 | F. Hoffmann-La Roche Ag | Process for galnac oligonucleotide conjugates |
WO2018216785A1 (ja) | 2017-05-26 | 2018-11-29 | 国立研究開発法人国立循環器病研究センター | Pcsk9を標的としたアンチセンス核酸 |
US20190055564A1 (en) | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
JP2020522265A (ja) * | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド組成物及びその使用方法 |
US11401519B2 (en) | 2017-06-07 | 2022-08-02 | University Of Massachusetts | Anti-ADAM33 oligonucleotides and related methods |
WO2019030574A1 (en) | 2017-08-10 | 2019-02-14 | Cerenis Therapeutics Holding | CARGOMÈRES |
WO2019030313A2 (en) | 2017-08-11 | 2019-02-14 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION |
AU2018318231A1 (en) | 2017-08-18 | 2020-02-13 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
WO2019038228A1 (en) | 2017-08-22 | 2019-02-28 | Roche Innovation Center Copenhagen A/S | OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | MODULATORS OF SMAD7 EXPRESSION |
US11596646B2 (en) | 2017-10-12 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
EP3694995A1 (en) | 2017-10-13 | 2020-08-19 | Roche Innovation Center Copenhagen A/S | Methods for identifying improved stereodefined phosphorothioate oligonucleotide variants of antisense oligonucleotides utilising sub-libraries of partially stereodefined oligonucleotides |
AU2018350693B2 (en) | 2017-10-16 | 2021-03-04 | F. Hoffmann-La Roche Ag | Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection |
CA3081758A1 (en) | 2017-11-06 | 2019-05-09 | Nitto Denko Corporation | Fusogenic compounds for delivery of biologically active molecules |
TWI809004B (zh) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | 用於降低snca表現之化合物及方法 |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
EP3719127A4 (en) | 2017-12-01 | 2021-10-20 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH IT, MANUFACTURING METHOD AND USE |
CA3083526A1 (en) | 2017-12-06 | 2019-06-13 | Andrew John Geall | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
WO2019115416A2 (en) | 2017-12-11 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating fndc3b expression |
WO2019115417A2 (en) | 2017-12-12 | 2019-06-20 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating rb1 expression |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
MX2020005872A (es) | 2017-12-21 | 2020-08-13 | Hoffmann La Roche | Diagnostico complementario para antagonistas de acido ribonucleico (arn) de proteina a1 de alto requerimiento de temperatura a (htra1). |
KR20200104345A (ko) | 2017-12-22 | 2020-09-03 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드 |
EP4092117A1 (en) | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
EP4092118A1 (en) | 2017-12-22 | 2022-11-23 | Roche Innovation Center Copenhagen A/S | Novel thiophosphoramidites |
KR102617947B1 (ko) * | 2017-12-29 | 2023-12-27 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 접합체와 제조 및 그 용도 |
WO2019137883A1 (en) | 2018-01-10 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating pias4 expression |
CA3085964A1 (en) | 2018-01-12 | 2019-07-18 | Roche Innovation Center Copenhagen A/S | Alpha-synuclein antisense oligonucleotides and uses thereof |
KR20200140240A (ko) | 2018-01-12 | 2020-12-15 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시누클레인을 표적화하는 안티센스 올리고뉴클레오티드 및 그의 용도 |
PE20201501A1 (es) | 2018-01-12 | 2020-12-29 | Bristol Myers Squibb Co | Oligonucleotidos antisentido que actuan sobre alfa-sinucleina, y usos de estos |
US20210095275A1 (en) | 2018-01-12 | 2021-04-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating gsk3b expression |
RU2020127049A (ru) | 2018-01-15 | 2022-02-17 | Айонис Фармасьютикалс, Инк. | Модуляторы экспрессии dnm2 |
EP3740574A1 (en) | 2018-01-17 | 2020-11-25 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating erc1 expression |
JP2021511029A (ja) | 2018-01-18 | 2021-05-06 | ロシュ イノベーション センター コペンハーゲン エーエス | Srebp1を標的とするアンチセンスオリゴヌクレオチド |
WO2019145386A1 (en) | 2018-01-26 | 2019-08-01 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating csnk1d expression |
WO2019145384A1 (en) * | 2018-01-26 | 2019-08-01 | F. Hoffmann-La Roche Ag | Radiolabelled oligonucleotides and process for their preparation |
KR20200108315A (ko) | 2018-02-09 | 2020-09-17 | 제넨테크, 인크. | Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드 |
JP7500426B2 (ja) | 2018-02-21 | 2024-06-17 | ブリストル-マイヤーズ スクイブ カンパニー | Camk2dアンチセンスオリゴヌクレオチドおよびその使用 |
US11241451B2 (en) | 2018-03-02 | 2022-02-08 | Ionis Pharmaceuticals, Inc. | Modulators of IRF4 expression |
US11732260B2 (en) | 2018-03-02 | 2023-08-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-β precursor protein |
WO2019172286A1 (ja) | 2018-03-09 | 2019-09-12 | 第一三共株式会社 | 糖原病Ia型治療薬 |
US11661601B2 (en) | 2018-03-22 | 2023-05-30 | Ionis Pharmaceuticals, Inc. | Methods for modulating FMR1 expression |
MA52661A (fr) | 2018-04-05 | 2021-02-17 | Centre Leon Berard | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b |
AU2019252667A1 (en) | 2018-04-11 | 2020-10-01 | Ionis Pharmaceuticals, Inc. | Modulators of EZH2 expression |
EP3790991A1 (en) | 2018-05-07 | 2021-03-17 | Roche Innovation Center Copenhagen A/S | Massively parallel discovery methods for oligonucleotide therapeutics |
WO2019215175A1 (en) | 2018-05-08 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating myh7 expression |
TW202016302A (zh) | 2018-05-08 | 2020-05-01 | 美商雷格勒斯治療公司 | 用於調節mir-122之微小rna化合物及方法 |
EP3799602A4 (en) | 2018-05-09 | 2022-02-16 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION |
CU20200082A7 (es) | 2018-05-09 | 2021-06-08 | Ionis Pharmaceuticals Inc | Compuestos y métodos para la reducción de la expresión de fxi |
WO2019233921A1 (en) | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating atxn2 expression |
EP3807411A4 (en) | 2018-06-14 | 2022-08-03 | Ionis Pharmaceuticals, Inc. | COMPOUNDS AND METHODS FOR ENHANCING STMN2 EXPRESSION |
TWI833770B (zh) | 2018-06-27 | 2024-03-01 | 美商Ionis製藥公司 | 用於減少 lrrk2 表現之化合物及方法 |
WO2020007700A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting spi1 |
WO2020007772A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
WO2020007702A1 (en) | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting bcl2l11 |
JP7102557B2 (ja) | 2018-07-03 | 2022-07-19 | エフ.ホフマン-ラ ロシュ アーゲー | Tau発現調節用オリゴヌクレオチド |
WO2020007826A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mbtps1 |
WO2020007889A1 (en) | 2018-07-05 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting stat1 |
WO2020011743A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting mafb |
WO2020011653A1 (en) | 2018-07-09 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting kynu |
WO2020011745A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers6 |
WO2020011744A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting cers5 |
WO2020011869A2 (en) | 2018-07-11 | 2020-01-16 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting tlr2 |
SG11202100348SA (en) | 2018-07-13 | 2021-02-25 | Hoffmann La Roche | Oligonucleotides for modulating rtel1 expression |
WO2020023737A1 (en) | 2018-07-25 | 2020-01-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn2 expression |
AU2019313527A1 (en) | 2018-07-31 | 2021-02-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
AU2019313443A1 (en) * | 2018-07-31 | 2020-11-26 | Roche Innovation Center Copenhagen A/S | Oligonucleotides comprising a phosphorotrithioate internucleoside linkage |
MX2021001590A (es) | 2018-08-10 | 2021-07-02 | Univ Massachusetts | Oligonucleótidos modificados dirigidos a snp. |
JP2021533800A (ja) | 2018-08-21 | 2021-12-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用 |
EP3841220A1 (en) | 2018-08-23 | 2021-06-30 | Roche Innovation Center Copenhagen A/S | Microrna-134 biomarker |
WO2020038976A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting usp8 |
WO2020038973A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting sptlc1 |
WO2020038971A1 (en) | 2018-08-23 | 2020-02-27 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting vcan |
US20220160870A1 (en) | 2018-08-28 | 2022-05-26 | Roche Innovation Center Copenhagen A/S | Neoantigen engineering using splice modulating compounds |
EP3620519A1 (en) | 2018-09-04 | 2020-03-11 | F. Hoffmann-La Roche AG | Use of isolated milk extracellular vesicles for delivering oligonucleotides orally |
CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
CN112969709A (zh) | 2018-11-01 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 靶向tia1的反义寡核苷酸 |
TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
CR20210311A (es) | 2018-11-15 | 2021-07-22 | Ionis Pharmaceuticals Inc | Moduladores de la expresión de irf5 |
WO2020132521A1 (en) | 2018-12-20 | 2020-06-25 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of kcnt1 related disorders |
US20220042011A1 (en) | 2018-12-21 | 2022-02-10 | Hoffmann-La Roche Inc. | Antisense oligonucleotides targeting card9 |
CN113614232A (zh) * | 2019-01-18 | 2021-11-05 | 马萨诸塞大学 | 动态药代动力学修饰锚 |
WO2020152303A1 (en) | 2019-01-25 | 2020-07-30 | F. Hoffmann-La Roche Ag | Lipid vesicle for oral drug delivery |
CN113395971A (zh) | 2019-01-31 | 2021-09-14 | Ionis制药公司 | Yap1表达的调节剂 |
WO2020169696A1 (en) | 2019-02-20 | 2020-08-27 | Roche Innovation Center Copenhagen A/S | Novel phosphoramidites |
JP2022521510A (ja) * | 2019-02-20 | 2022-04-08 | ロシュ イノベーション センター コペンハーゲン エーエス | ホスホノアセテートギャップマー型オリゴヌクレオチド |
WO2020173845A1 (en) | 2019-02-26 | 2020-09-03 | Roche Innovation Center Copenhagen A/S | Oligonucleotide formulation method |
TW202045724A (zh) | 2019-02-27 | 2020-12-16 | 美商Ionis製藥公司 | Malat1表現之調節劑 |
US20220184216A1 (en) * | 2019-03-05 | 2022-06-16 | Hoffmann-La Roche Inc. | Intracellular targeting of molecules |
CA3135180A1 (en) | 2019-03-29 | 2020-10-08 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating ube3a-ats |
CA3132178A1 (en) | 2019-04-02 | 2020-10-08 | Aliye Seda Yilmaz-Elis | Antisense oligonucleotides for immunotherapy |
BR112021019182A2 (pt) | 2019-04-03 | 2022-05-31 | Bristol Myers Squibb Co | Oligonucleotídeos angptl2 antissenso e seus usos |
EP3947677A1 (en) | 2019-04-04 | 2022-02-09 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating atxn2 expression |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
PE20220574A1 (es) | 2019-05-31 | 2022-04-20 | Aligos Therapeutics Inc | Oligonucleotidos gapmer modificados y metodos de uso |
WO2020245233A1 (en) | 2019-06-06 | 2020-12-10 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
WO2021021673A1 (en) | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
US20230114023A1 (en) * | 2019-07-30 | 2023-04-13 | Mpeg La, L.L.C. | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
CN114616332A (zh) | 2019-09-10 | 2022-06-10 | 第一三共株式会社 | 用于递送至肝脏的GalNAc-寡核苷酸偶联物及其制备方法 |
AU2020356931A1 (en) * | 2019-10-02 | 2022-05-26 | Sirnaomics, Inc. | Oligonucleotides with nucleoside analogs |
EP4077668A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of scamp3 inhibitors for treating hepatitis b virus infection |
EP4077669A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of sbds inhibitors for treating hepatitis b virus infection |
WO2021122993A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of saraf inhibitors for treating hepatitis b virus infection |
WO2021127650A1 (en) * | 2019-12-19 | 2021-06-24 | Entrada Therapeutics, Inc. | Compositions for delivery of antisense compounds |
CN114901821A (zh) | 2019-12-19 | 2022-08-12 | 豪夫迈·罗氏有限公司 | Sept9抑制剂用于治疗乙型肝炎病毒感染的用途 |
EP4077670A1 (en) | 2019-12-19 | 2022-10-26 | F. Hoffmann-La Roche AG | Use of cops3 inhibitors for treating hepatitis b virus infection |
CN114829603A (zh) | 2019-12-20 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于抑制scn9a表达的增强寡核苷酸 |
MX2022007908A (es) | 2019-12-24 | 2022-07-21 | Hoffmann La Roche | Combinacion farmaceutica de un oligonucleotido terapeutico que actua sobre hbv y un agonista de tlr7 para el tratamiento de hbv. |
MX2022007909A (es) | 2019-12-24 | 2022-07-21 | Hoffmann La Roche | Combinacion farmaceutica de agentes antivirales que actuan sobre hbv y/o un inmunomodulador para el tratamiento de hbv. |
US20230090446A1 (en) | 2020-01-28 | 2023-03-23 | Universite De Strasbourg | Antisense oligonucleotide targeting linc00518 for treating melanoma |
WO2021158810A1 (en) | 2020-02-05 | 2021-08-12 | Bristol-Myers Squibb Company | Oligonucleotides for splice modulation of camk2d |
CN115279379A (zh) | 2020-02-28 | 2022-11-01 | Ionis 制药公司 | 用于调节smn2的化合物和方法 |
JP2023516142A (ja) | 2020-02-28 | 2023-04-18 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Cd73エクソン7スプライシングを調節するためのオリゴヌクレオチド |
JP2023537798A (ja) | 2020-03-19 | 2023-09-06 | アビディティー バイオサイエンシーズ,インク. | 顔面肩甲上腕型筋ジストロフィーを処置するための組成物および方法 |
CN115916262A (zh) * | 2020-04-21 | 2023-04-04 | 旗舰创业股份有限公司 | 双官能分子及其使用方法 |
JP2023524065A (ja) | 2020-05-01 | 2023-06-08 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Atxn1を調節するための化合物及び方法 |
JP2023527693A (ja) | 2020-05-11 | 2023-06-30 | ジェネンテック, インコーポレイテッド | 神経疾患を治療するための補体成分c1r阻害剤、並びに関連する組成物、システム、及びそれを使用する方法 |
EP4149486A1 (en) | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
EP4150084A1 (en) | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same |
JP2023526267A (ja) | 2020-05-13 | 2023-06-21 | エフ. ホフマン-ラ ロシュ アーゲー | プログラニュリン標的オリゴヌクレオチドアゴニスト |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
WO2021231673A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
WO2021231685A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
EP4150088A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
JP2023526096A (ja) | 2020-05-22 | 2023-06-20 | エフ. ホフマン-ラ ロシュ アーゲー | Card9のスプライス調節のためのオリゴヌクレオチド |
US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
CN115702243A (zh) | 2020-06-09 | 2023-02-14 | 罗氏创新中心哥本哈根有限公司 | 用于治疗性多核苷酸的鸟苷类似物 |
AR122731A1 (es) | 2020-06-26 | 2022-10-05 | Hoffmann La Roche | Oligonucleótidos mejorados para modular la expresión de fubp1 |
AU2021299290A1 (en) | 2020-06-29 | 2023-01-05 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating PLP1 |
WO2022018155A1 (en) | 2020-07-23 | 2022-01-27 | F. Hoffmann-La Roche Ag | Lna oligonucleotides for splice modulation of stmn2 |
JP2023534557A (ja) | 2020-07-23 | 2023-08-09 | エフ. ホフマン-ラ ロシュ アーゲー | Rna結合タンパク質部位を標的とするオリゴヌクレオチド |
CN111671913B (zh) * | 2020-07-30 | 2022-02-08 | 四川大学 | 一种量子点-小核酸偶联物及其用途 |
EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
JP2023545406A (ja) * | 2020-10-02 | 2023-10-30 | サーナオミクス インコーポレイテッド | ウイルス性疾患を治療するためのヌクレオシド含有siRNA |
IL302817A (en) | 2020-11-18 | 2023-07-01 | Ionis Pharmaceuticals Inc | Compounds and methods for modulating angiotensinogen expression |
AR124227A1 (es) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | Oligonucleótidos antisentido que actúan sobre atxn3 |
AR124229A1 (es) | 2020-12-03 | 2023-03-01 | Hoffmann La Roche | Oligonucleótidos antisentido que actúan sobre atxn3 |
AR124378A1 (es) | 2020-12-18 | 2023-03-22 | Hoffmann La Roche | Oligonucleótidos antisentido dirigida a progranulina |
WO2022136140A1 (en) | 2020-12-22 | 2022-06-30 | F. Hoffmann-La Roche Ag | Oligonucleotides targeting xbp1 |
CN114716518A (zh) * | 2021-01-06 | 2022-07-08 | 圣诺制药公司 | 一种能够抑制pcsk9表达的分子构造及药物组合物 |
WO2022162015A1 (en) | 2021-01-26 | 2022-08-04 | Universite Brest Bretagne Occidentale | Novel stim1 splicing variants and uses thereof |
TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 rtel1 表現之增強型寡核苷酸 |
PE20240696A1 (es) | 2021-03-08 | 2024-04-10 | Servier Lab | Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina |
WO2022232650A1 (en) * | 2021-04-30 | 2022-11-03 | Ionis Pharmaceuticals, Inc. | Methods for reducing agt expression |
EP4341405A1 (en) | 2021-05-20 | 2024-03-27 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
WO2022258555A1 (en) | 2021-06-08 | 2022-12-15 | F. Hoffmann-La Roche Ag | Oligonucleotide progranulin agonists |
CA3223192A1 (en) | 2021-06-18 | 2022-12-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
WO2022271786A1 (en) | 2021-06-23 | 2022-12-29 | University Of Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2023034561A2 (en) * | 2021-09-02 | 2023-03-09 | Vanderbilt University | Lipophilic oligonucleotide conjugates |
AU2022345098A1 (en) | 2021-09-16 | 2024-04-04 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023078883A1 (en) | 2021-11-03 | 2023-05-11 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating apolipoprotein e4 expression |
CA3234478A1 (en) | 2021-11-11 | 2023-05-19 | Souphalone LUANGSAY | Pharmaceutical combinations for treatment of hbv |
WO2023102188A1 (en) * | 2021-12-03 | 2023-06-08 | Quralis Corporation | Gapmer antisense oligonucleotides with modified backbone chemistries |
WO2023104693A1 (en) | 2021-12-07 | 2023-06-15 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting actl6b |
WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
WO2023111336A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Oligonucleotide gba agonists |
WO2023117738A1 (en) | 2021-12-20 | 2023-06-29 | F. Hoffmann-La Roche Ag | Threose nucleic acid antisense oligonucleotides and methods thereof |
WO2023141507A1 (en) | 2022-01-20 | 2023-07-27 | Genentech, Inc. | Antisense oligonucleotides for modulating tmem106b expression |
US20240167040A1 (en) | 2022-02-21 | 2024-05-23 | Hoffmann-La Roche Inc. | Antisense oligonucleotide |
WO2023217890A1 (en) | 2022-05-10 | 2023-11-16 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting cfp-elk1 intergene region |
TW202409276A (zh) | 2022-05-18 | 2024-03-01 | 瑞士商赫孚孟拉羅股份公司 | 改良之靶向rna結合蛋白位點的寡核苷酸 |
WO2023242324A1 (en) | 2022-06-17 | 2023-12-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for targeting progranulin |
EP4332221A1 (en) | 2022-08-29 | 2024-03-06 | Roche Innovation Center Copenhagen A/S | Threose nucleic acid antisense oligonucleotides and methods thereof |
WO2024052403A1 (en) | 2022-09-06 | 2024-03-14 | F. Hoffmann-La Roche Ag | Double-stranded rna molecule for administration to the eye |
Family Cites Families (207)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US603095A (en) | 1898-04-26 | Machine for dishing metal | ||
US2699808A (en) | 1944-10-06 | 1955-01-18 | Mark W Lowe | Apparatus for peeling tomatoes |
US2699508A (en) | 1951-12-21 | 1955-01-11 | Selectronics Inc | Method of mounting and construction of mounting for low frequency piezoelectric crystals |
JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
US5714166A (en) | 1986-08-18 | 1998-02-03 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates |
US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
ATE198598T1 (de) | 1990-11-08 | 2001-01-15 | Hybridon Inc | Verbindung von mehrfachreportergruppen auf synthetischen oligonukleotiden |
DE4104186A1 (de) | 1991-02-12 | 1992-08-13 | Genentech Inc | Neue, ueber endozytose in hoehere eukaryotische zellen aufnehmbare, nukleinsaeure enthaltende komplexe |
DE4110409C2 (de) | 1991-03-29 | 1999-05-27 | Boehringer Ingelheim Int | Neue Protein-Polykation-Konjugate |
KR950014915B1 (ko) | 1991-06-19 | 1995-12-18 | 주식회사녹십자 | 탈시알로당단백-포함화합물 |
EP1331011A3 (en) | 1991-10-24 | 2003-12-17 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
CA2170869C (en) | 1993-09-03 | 1999-09-14 | Phillip Dan Cook | Amine-derivatized nucleosides and oligonucleosides |
US5646262A (en) | 1994-07-28 | 1997-07-08 | Georgetown University | Antisense oligonucleotides against hepatitis B viral replication |
US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
EP0804456B1 (en) | 1994-10-06 | 2002-08-21 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
US5684142A (en) | 1995-06-07 | 1997-11-04 | Oncor, Inc. | Modified nucleotides for nucleic acid labeling |
US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
US5985662A (en) | 1995-07-13 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense inhibition of hepatitis B virus replication |
WO1997020563A1 (en) | 1995-11-22 | 1997-06-12 | The Johns-Hopkins University | Ligands to enhance cellular uptake of biomolecules |
US6344436B1 (en) | 1996-01-08 | 2002-02-05 | Baylor College Of Medicine | Lipophilic peptides for macromolecule delivery |
US5656408A (en) | 1996-04-29 | 1997-08-12 | Xerox Corporation | Coated carrier particles |
US5776907A (en) | 1996-05-20 | 1998-07-07 | Texas Biotechnology Corporation | Mitomycin oligonucleotide conjugates |
US7875733B2 (en) | 2003-09-18 | 2011-01-25 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation |
US6001991A (en) * | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
US20030014318A1 (en) | 1996-11-08 | 2003-01-16 | Matthew Byrne | International trading system and method |
US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
US5770716A (en) | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
BR9809242A (pt) * | 1997-05-05 | 2000-06-27 | Hoechst Marion Russel Deutschl | Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano |
BR9809138A (pt) | 1997-05-21 | 2001-08-28 | Trustees For The Leland Stanfo | Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica |
US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
CN1273476C (zh) | 1997-09-12 | 2006-09-06 | 埃克西康有限公司 | 寡核苷酸类似物 |
US6096875A (en) | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
US6300319B1 (en) | 1998-06-16 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Targeted oligonucleotide conjugates |
US6335432B1 (en) | 1998-08-07 | 2002-01-01 | Bio-Red Laboratories, Inc. | Structural analogs of amine bases and nucleosides |
US6335437B1 (en) | 1998-09-07 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Methods for the preparation of conjugated oligomers |
US6365379B1 (en) | 1998-10-06 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Zinc finger peptide cleavage of nucleic acids |
WO2000032764A1 (en) | 1998-12-02 | 2000-06-08 | I.D.M. Immuno-Designed Molecules | New oligomeric conjugates liable to transfer biological molecules into cells |
ATE356824T1 (de) | 1999-05-04 | 2007-04-15 | Santaris Pharma As | L-ribo-lna analoge |
US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US20040146516A1 (en) | 1999-06-17 | 2004-07-29 | Utah Ventures Ii L.P. | Lumen-exposed molecules and methods for targeted delivery |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
WO2001025248A2 (en) | 1999-10-04 | 2001-04-12 | Exiqon A/S | Design of high affinity rnase h recruiting oligonucleotide |
US20080039414A1 (en) | 2002-02-20 | 2008-02-14 | Sima Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US6559279B1 (en) | 2000-09-08 | 2003-05-06 | Isis Pharmaceuticals, Inc. | Process for preparing peptide derivatized oligomeric compounds |
EP1383782A1 (en) | 2001-03-26 | 2004-01-28 | Sirna Therpeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
EP3231445A1 (en) | 2001-05-18 | 2017-10-18 | Sirna Therapeutics, Inc. | Conjugates and compositions for cellular delivery |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7259150B2 (en) | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US20030191075A1 (en) | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
WO2003097662A1 (en) | 2002-05-15 | 2003-11-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
GB2389824B (en) | 2002-06-21 | 2005-08-24 | Paul Sinclair | Improvements in or relating to funeral vehicles |
US7655790B2 (en) * | 2002-07-12 | 2010-02-02 | Sirna Therapeutics, Inc. | Deprotection and purification of oligonucleotides and their derivatives |
US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
US6878805B2 (en) | 2002-08-16 | 2005-04-12 | Isis Pharmaceuticals, Inc. | Peptide-conjugated oligomeric compounds |
EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
CA2505090A1 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Conjugated oligomeric compounds and their use in gene modulation |
WO2004044132A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Modified oligonucleotides for use in rna interference |
WO2004044181A2 (en) | 2002-11-13 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein b expression |
US7511131B2 (en) * | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
DK3222722T3 (da) | 2002-11-18 | 2019-06-17 | Roche Innovation Ct Copenhagen As | Antisense-design |
US7816337B2 (en) | 2003-02-18 | 2010-10-19 | Roche Madison Inc. | Reversible attachment of a membrane active polymer to a polynucleotide |
AU2003219576A1 (en) | 2003-04-03 | 2004-10-25 | Korea Advanced Institute Of Science And Technology | Conjugate for gene transfer comprising oligonucleotide and hydrophilic polymer, polyelectrolyte complex micelles formed from the conjugate, and methods for preparation thereof |
US7723509B2 (en) | 2003-04-17 | 2010-05-25 | Alnylam Pharmaceuticals | IRNA agents with biocleavable tethers |
WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
BRPI0410886A (pt) * | 2003-06-03 | 2006-07-04 | Isis Pharmaceuticals Inc | composto de filamento duplo, composição farmacêutica, sal farmaceuticamente aceitável, métodos de modificação do ácido nucleico que codifica a survivina humana, de inibição da expressão da suvivina em células ou tecidos, e de tratamento de uma condição associada com a expressão ou superexpressão da suvivina, e, oligonucleotìdeo de rnai de filamento único |
DK1495769T3 (da) | 2003-07-11 | 2008-06-23 | Lbr Medbiotech B V | Mannose-6-phosphat-receptormedieret gentransfer til muskelceller |
US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
US7427672B2 (en) | 2003-08-28 | 2008-09-23 | Takeshi Imanishi | Artificial nucleic acids of n-o bond crosslinkage type |
JP4989225B2 (ja) * | 2003-09-25 | 2012-08-01 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 核酸親油性接合体 |
ATE467679T1 (de) | 2003-12-23 | 2010-05-15 | Santaris Pharma As | Oligomere verbindungen zur modulation von bcl-2 |
CA2553221A1 (en) | 2004-01-22 | 2005-08-04 | Immunomedics, Inc. | Folate conjugates and complexes |
DK1713912T3 (da) | 2004-01-30 | 2013-12-16 | Santaris Pharma As | Modificerede Korte Interfererende RNA (Modificerede siRNA) |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
EP1737879B1 (en) | 2004-04-19 | 2012-10-10 | Archemix LLC | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides |
US20050288246A1 (en) | 2004-05-24 | 2005-12-29 | Iversen Patrick L | Peptide conjugated, inosine-substituted antisense oligomer compound and method |
US7632932B2 (en) | 2004-08-04 | 2009-12-15 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase |
EP1786472B1 (en) | 2004-08-10 | 2013-01-16 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
WO2006036916A2 (en) * | 2004-09-24 | 2006-04-06 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of apob and uses thereof |
DE602005022768D1 (de) * | 2004-11-09 | 2010-09-16 | Santaris Pharma As | Wirksame lna-oligonukleotide zur inhibierung von hif-1a |
EP1824975B9 (en) * | 2004-11-09 | 2011-04-20 | Santaris Pharma A/S | Lna oligonucleotides and the treatment of cancer |
US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
JP2008527993A (ja) | 2005-01-24 | 2008-07-31 | アヴァリス・アクチエボラーグ | 特異性及び送達の改善のためのsiRNA分子、shRNA分子又はアンチセンス分子及び機能的実体を含む複合体 |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
ATE494372T1 (de) | 2005-08-29 | 2011-01-15 | Regulus Therapeutics Inc | Verfahren für mir-122a-modulation |
WO2007027894A2 (en) | 2005-08-29 | 2007-03-08 | Isis Pharmaceuticals, Inc. | Antisense compounds having enhanced anti-microrna activity |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
US20090118213A1 (en) * | 2005-09-15 | 2009-05-07 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
EA200800868A1 (ru) | 2005-09-19 | 2008-10-30 | ДЖОНСОН ЭНД ДЖОНСОН ФАРМАСЬЮТИКАЛ РИСЕРЧ ЭНД ДИВЕЛОПМЕНТ, Эл. Эл. Си. | Модуляция экспрессии глюкокортикоидного рецептора |
CA2629323A1 (en) | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
WO2007085485A2 (en) | 2006-01-27 | 2007-08-02 | Santaris Pharma A/S | Lna modified phosphorothiolated oligonucleotides |
CN102908630B (zh) | 2006-01-27 | 2014-11-19 | Isis制药公司 | 6-修饰的双环核酸类似物 |
EP2089521A1 (en) | 2006-02-08 | 2009-08-19 | Ercole Biotech, Inc. | Soluble tnf receptors and their use in treatment of disease |
AU2007229161B2 (en) | 2006-03-23 | 2012-07-12 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering RNA |
GB0606415D0 (en) | 2006-03-31 | 2006-05-10 | Univ Southampton | Topical drug delivery |
ES2715625T3 (es) | 2006-04-03 | 2019-06-05 | Roche Innovation Ct Copenhagen As | Composición farmacéutica que comprende oligonucleótidos antisentido anti-miARN |
MY162210A (en) * | 2006-04-03 | 2017-05-31 | Roche Innovation Ct Copenhagen As | Pharmaceutical composition |
AU2007257093A1 (en) | 2006-05-05 | 2007-12-13 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of PCSK9 |
EP2066684B1 (en) | 2006-05-11 | 2012-07-18 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
CN101534643A (zh) | 2006-09-15 | 2009-09-16 | 安佐制药股份有限公司 | 用于递送寡核苷酸的基于位阻酯的生物可降解连接体 |
BRPI0716823A2 (pt) | 2006-09-15 | 2015-05-26 | Enzon Pharmaceuticals Inc | Conjunto poliméricos contendo porções positivamente carregadas |
KR101251707B1 (ko) * | 2006-09-27 | 2013-04-11 | 콜리 파마슈티칼 게엠베하 | 면역 자극 활성이 증강된 소수성 T 유사체를 함유하는 CpG 올리고뉴클레오티드 유사체 |
WO2008040355A2 (en) | 2006-10-06 | 2008-04-10 | Exiqon A/S | Novel methods for quantification of micrornas and small interfering rnas |
ES2603379T3 (es) | 2006-10-09 | 2017-02-27 | Roche Innovation Center Copenhagen A/S | Compuestos antagonistas de ARN para la modulación de PCSK9 |
EP2455471A3 (en) | 2006-11-27 | 2012-09-12 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
WO2008109369A2 (en) | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting tnf gene expression and uses thereof |
DE102007012908A1 (de) | 2007-03-19 | 2008-09-25 | Momentive Performance Materials Gmbh | Neue Polyamid-Polysiloxan-Verbindungen |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
WO2008113830A1 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
CN103480002A (zh) * | 2007-03-24 | 2014-01-01 | 基酶有限公司 | 施用与人载脂蛋白 b互补的反义寡核苷酸 |
DK2152879T3 (da) | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
KR20150036814A (ko) | 2007-05-01 | 2015-04-07 | 산타리스 팔마 에이/에스 | Tnf 슈퍼패밀리 수용체에 대한 스플라이스 스위칭 올리고머 및 질병 치료에 있어서의 그의 용도 |
US8278425B2 (en) | 2007-05-30 | 2012-10-02 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
WO2008154401A2 (en) | 2007-06-08 | 2008-12-18 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
US20090099066A1 (en) | 2007-06-29 | 2009-04-16 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
DK2176280T4 (en) | 2007-07-05 | 2015-07-20 | Isis Pharmaceuticals Inc | 6-Disubstituerede bicykliske nukleinsyreanaloge |
EP2171648A4 (en) | 2007-07-19 | 2011-06-29 | Datakey Electronics Inc | HF TOKEN AND RECORDING SYSTEM AND METHOD |
MX2010001955A (es) | 2007-08-20 | 2010-03-10 | Enzon Pharmaceuticals Inc | Enlazadores polimericos que contienen porciones de disulfuro-piridilo. |
US8486904B2 (en) | 2007-10-01 | 2013-07-16 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
KR101889518B1 (ko) | 2007-10-04 | 2018-08-17 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 마이크로MIRs |
WO2009045536A2 (en) | 2007-10-05 | 2009-04-09 | The University Of North Carolina At Chapel Hill | Receptor targeted oligonucleotides |
DK2225377T3 (da) | 2007-11-26 | 2014-04-07 | Santaris Pharma As | Lna-antagonister, der er målrettet mod androgenreceptoren |
CA2707539A1 (en) | 2007-12-03 | 2009-06-11 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of pik3ca expression |
US20090247608A1 (en) | 2007-12-04 | 2009-10-01 | Alnylam Pharmaceuticals, Inc. | Targeting Lipids |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
CA2717792A1 (en) | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
WO2009124238A1 (en) | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
JP5788312B2 (ja) | 2008-04-11 | 2015-09-30 | アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 標的リガンドをエンドソーム分解性成分と組み合わせることによる核酸の部位特異的送達 |
WO2009148605A2 (en) | 2008-06-04 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
JP2011526482A (ja) | 2008-07-03 | 2011-10-13 | サンタリス ファーマ アー/エス | ミトコンドリアグリセロール−3−リン酸アシルトランスフェラーゼ1(mtgpat1)の発現を阻害するためのrnaアンタゴニスト化合物 |
AU2009270020B2 (en) | 2008-07-10 | 2014-09-25 | Regenesance B.V. | Complement antagonists and uses thereof |
US9033197B2 (en) | 2008-07-17 | 2015-05-19 | Nir Bar | Spool holder |
US7932256B2 (en) | 2008-07-31 | 2011-04-26 | Bristol-Myers Squibb Company | (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity |
US20110237646A1 (en) | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
US20120022245A1 (en) | 2008-10-17 | 2012-01-26 | Purdue Research Foundation | Folate targeting of nucleotides |
US9132147B2 (en) | 2008-12-31 | 2015-09-15 | Roche Innovation Center Copenhagen | Use of LNA ApoB antisense oligomers for the treatment of acute coronary syndromes |
AT507215B1 (de) | 2009-01-14 | 2010-03-15 | Boehler Edelstahl Gmbh & Co Kg | Verschleissbeständiger werkstoff |
WO2010120508A2 (en) | 2009-03-31 | 2010-10-21 | The General Hospital Corporation | Regulation of mir-33 micrornas in the treatment of cholesterol-related disorders |
EP2421970B1 (en) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
MX2011013078A (es) | 2009-06-12 | 2012-02-01 | Santaris Pharma As | Nuevos compuestos potentes antisentido anti apolipoproteina b (apob). |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
WO2011047312A1 (en) | 2009-10-16 | 2011-04-21 | Glaxo Group Limited | Hbv antisense inhibitors |
KR101663617B1 (ko) | 2009-10-29 | 2016-10-07 | 엘지전자 주식회사 | 하향링크 기준신호 송수신 방법 및, 이를 이용한 기지국 및 사용자기기 |
US20130023578A1 (en) * | 2009-12-31 | 2013-01-24 | Samyang Biopharmaceuticals Corporation | siRNA for inhibition of c-Met expression and anticancer composition containing the same |
CN106146591B (zh) | 2010-01-08 | 2020-07-31 | Ionis制药公司 | 血管生成素样3表达的调节 |
WO2011088309A1 (en) | 2010-01-14 | 2011-07-21 | Regulus Therapeutics Inc. | Microrna compositions and methods |
JP6137834B2 (ja) | 2010-02-24 | 2017-05-31 | アローヘッド ファーマシューティカルズ インコーポレイテッド | siRNAの標的化送達のための組成物 |
WO2011123621A2 (en) | 2010-04-01 | 2011-10-06 | Alnylam Pharmaceuticals Inc. | 2' and 5' modified monomers and oligonucleotides |
WO2011126937A1 (en) | 2010-04-06 | 2011-10-13 | The University Of North Carolina At Chapel Hill | Targeted intracellular delivery of oligonucleotides via conjugation with small molecule ligands |
WO2011130458A2 (en) * | 2010-04-13 | 2011-10-20 | John Rossi | Rna aptamers against baff-r as cell-type specific delivery agents and methods for their use |
US9193969B2 (en) | 2010-04-19 | 2015-11-24 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
NZ603339A (en) | 2010-04-29 | 2015-01-30 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression |
US8815826B2 (en) | 2010-07-23 | 2014-08-26 | Regulus Therapeutics, Inc. | Targeting microRNAs for the treatment of fibrosis |
US9127280B2 (en) * | 2010-08-31 | 2015-09-08 | Osaka University | Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient |
US10378016B2 (en) | 2010-12-06 | 2019-08-13 | Children's Medical Center Corporation | Composition and method for oligonucleotide delivery |
EP3226459B1 (en) | 2010-12-13 | 2020-11-25 | Telefonaktiebolaget LM Ericsson (publ) | Exchange of parameters relating to measurement periods |
WO2012083046A2 (en) | 2010-12-17 | 2012-06-21 | Arrowhead Research Corporation | Galactose cluster-pharmacokinetic modulator targeting moiety for sirna |
AU2011352204B2 (en) | 2010-12-29 | 2015-05-21 | Arrowhead Pharmaceuticals, Inc. | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |
BR112013016761B1 (pt) | 2010-12-29 | 2021-04-06 | F. Hoffmann-La Roche Ag | Uso de um composto, composto e composição farmacêutica |
AU2012207606B2 (en) | 2011-01-11 | 2017-02-23 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
KR102055331B1 (ko) | 2011-04-21 | 2019-12-12 | 아이오니스 파마수티컬즈, 인코포레이티드 | B형 간염 바이러스(hbv) 발현 조절 |
TW201303013A (zh) | 2011-04-21 | 2013-01-16 | Isis Pharmaceuticals Inc | B型肝炎病毒(hbv)表現之調節 |
BR112013027187A2 (pt) | 2011-04-25 | 2017-06-06 | Regulus Therapeutics Inc | composto que compreende um oligonucleotídeo modificado complementar a mir-21; oligonucleotídeo modificado; composição farmacêutica; método para diminuir a expressão de colágeno em uma célula; e uso de um composto |
CN102226185A (zh) * | 2011-05-09 | 2011-10-26 | 华中科技大学同济医学院附属同济医院 | 靶向肝细胞的rna适配子及其核苷酸序列 |
WO2012174154A1 (en) | 2011-06-13 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Modulation of inflammatory responses by factor vii |
CA2839437A1 (en) | 2011-06-16 | 2012-12-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of fibroblast growth factor receptor 4 expression |
TWI695066B (zh) | 2011-06-30 | 2020-06-01 | 美商艾羅海德製藥公司 | 用於抑制b型肝炎病毒基因表現之組合物及方法 |
EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
DK2756080T3 (da) * | 2011-09-14 | 2019-05-20 | Translate Bio Ma Inc | Multimeriske oligonukleotidforbindelser |
AU2012327227A1 (en) | 2011-11-07 | 2013-05-23 | Isis Pharmaceuticals, Inc. | Administration of Factor XI antisense oligonucleotides |
WO2013068348A1 (en) | 2011-11-07 | 2013-05-16 | Santaris Pharma A/S | Lna oligomers for improvement in hepatic function |
CA2863958A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating factor vii expression |
WO2013142514A1 (en) | 2012-03-19 | 2013-09-26 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
US9984408B1 (en) | 2012-05-30 | 2018-05-29 | Amazon Technologies, Inc. | Method, medium, and system for live video cooperative shopping |
AU2013346767B2 (en) * | 2012-11-15 | 2019-04-11 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
RU2018108405A (ru) | 2013-01-30 | 2019-02-26 | Ф. Хоффманн-Ля Рош Аг | Конъюгаты углевода и lna-олигонуклеотида |
NZ631552A (en) | 2013-05-01 | 2017-02-24 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv expression |
CA2928349A1 (en) | 2013-11-14 | 2015-05-21 | Roche Innovation Center Copenhagen A/S | Apob antisense conjugate compounds |
US9778708B1 (en) | 2016-07-18 | 2017-10-03 | Lenovo Enterprise Solutions (Singapore) Pte. Ltd. | Dual sided latching retainer for computer modules |
-
2013
- 2013-11-14 AU AU2013346767A patent/AU2013346767B2/en not_active Ceased
- 2013-11-14 SI SI201331429T patent/SI2920304T1/sl unknown
- 2013-11-14 NZ NZ70817113A patent/NZ708171A/en unknown
- 2013-11-14 SG SG10201804331TA patent/SG10201804331TA/en unknown
- 2013-11-14 DK DK13794852.7T patent/DK2920307T3/en active
- 2013-11-14 CN CN201380059599.XA patent/CN104837996A/zh active Pending
- 2013-11-14 MY MYPI2015701549A patent/MY173826A/en unknown
- 2013-11-14 CA CA2889044A patent/CA2889044A1/en not_active Abandoned
- 2013-11-14 RU RU2015119409A patent/RU2653438C2/ru active
- 2013-11-14 KR KR1020157015641A patent/KR20150083920A/ko not_active Application Discontinuation
- 2013-11-14 US US14/443,369 patent/US20150291958A1/en not_active Abandoned
- 2013-11-14 ES ES13791808T patent/ES2724853T3/es active Active
- 2013-11-14 CN CN202310648137.7A patent/CN117126846A/zh active Pending
- 2013-11-14 KR KR1020157015912A patent/KR102112892B1/ko active IP Right Grant
- 2013-11-14 RU RU2018112970A patent/RU2018112970A/ru not_active Application Discontinuation
- 2013-11-14 MX MX2015005794A patent/MX363068B/es unknown
- 2013-11-14 SG SG11201503821YA patent/SG11201503821YA/en unknown
- 2013-11-14 RU RU2015119411A patent/RU2015119411A/ru not_active Application Discontinuation
- 2013-11-14 EP EP13794852.7A patent/EP2920307B1/en not_active Not-in-force
- 2013-11-14 CA CA2889596A patent/CA2889596C/en active Active
- 2013-11-14 BR BR112015011112-2A patent/BR112015011112A2/pt not_active Application Discontinuation
- 2013-11-14 US US14/443,367 patent/US10077443B2/en active Active
- 2013-11-14 MX MX2015005792A patent/MX2015005792A/es unknown
- 2013-11-14 PL PL13791808T patent/PL2920304T3/pl unknown
- 2013-11-14 JP JP2015542264A patent/JP6452614B2/ja active Active
- 2013-11-14 EP EP13791808.2A patent/EP2920304B1/en active Active
- 2013-11-14 CN CN201380069256.1A patent/CN104884618A/zh active Pending
- 2013-11-14 BR BR112015010116A patent/BR112015010116A2/pt not_active IP Right Cessation
- 2013-11-14 DK DK13791808.2T patent/DK2920304T3/da active
- 2013-11-14 EP EP18178292.1A patent/EP3406718A1/en not_active Withdrawn
- 2013-11-14 JP JP2015542265A patent/JP2016503300A/ja not_active Ceased
- 2013-11-14 WO PCT/EP2013/073858 patent/WO2014076195A1/en active Application Filing
- 2013-11-14 WO PCT/EP2013/073859 patent/WO2014076196A1/en active Application Filing
-
2015
- 2015-04-26 IL IL238448A patent/IL238448B/en active IP Right Grant
- 2015-05-14 ZA ZA2015/03375A patent/ZA201503375B/en unknown
- 2015-11-03 HK HK15110830.6A patent/HK1210213A1/xx unknown
-
2016
- 2016-02-25 HK HK16102154.0A patent/HK1214297A1/zh unknown
-
2018
- 2018-05-08 US US15/974,086 patent/US11155816B2/en active Active
- 2018-12-11 JP JP2018231244A patent/JP2019055995A/ja active Pending
-
2019
- 2019-04-03 AU AU2019202288A patent/AU2019202288A1/en not_active Abandoned
- 2019-05-03 HR HRP20190826TT patent/HRP20190826T1/hr unknown
- 2019-08-01 IL IL268420A patent/IL268420A/en unknown
-
2021
- 2021-02-25 US US17/185,820 patent/US20210238601A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL268420A (en) | Oligonucleotide conjugates | |
HUS2300020I1 (hu) | Pirrolobenzodiazepin-antitest konjugátumok | |
IL263973B (en) | Protein-polymer-drug conjugates | |
ZA201502523B (en) | Pyrrolobenzodiazepine-anitbody conjugates | |
DK2922554T3 (en) | Terminalt modificeret rna | |
HK1196257A1 (zh) | -抗體結合物 | |
IL228404A0 (en) | Antibody-drug captures | |
EP2920167A4 (en) | HYDRAZINYL-INDOLES AND CONJUGATED COMPOUNDS | |
EP2816053A4 (en) | OLIGONUCLEOTIDE PROTECTED BY A BASE | |
HK1204555A1 (en) | Conjugation reagents | |
ZA201409119B (en) | Polymer-nsaid conjugate | |
HK1204524A1 (en) | Line design | |
EP2891717A4 (en) | Oligonucleotide | |
EP2836238A4 (en) | COPOLYMERKONJUGATE | |
EP2928903A4 (en) | OLIGONUKLEOTIDREZEPTUR |